Table of Contents
Lung Cancer International
Volume 2014, Article ID 891917, 7 pages
http://dx.doi.org/10.1155/2014/891917
Research Article

Association between Argyrophilic Proteins of Nucleolar Organizer Regions, Clinicomorphological Parameters, and Survival in Non-Small-Cell Lung Cancer

1Molecular Diagnostic Laboratory at Altay, N.N. Blokhin ROSC (Russian Oncologic Scientific Center), RAMS (Russian Academy of Medical Sciences), Barnaul 656049, Russia
2Pathologic Anatomy Chair, Altay Medical University, Barnaul 656038, Russia
3General Pathologic Anatomy Laboratory, Cell Biology and Cytology Laboratory, Institute of Regional Pathology and Pathomorphology SB RAMS, Novosibirsk 630117, Russia

Received 13 June 2013; Accepted 2 December 2013; Published 2 January 2014

Academic Editor: Elisabeth Quoix

Copyright © 2014 Dmitriy Kobyakov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We studied argyrophilic proteins associated with nucleolar organizer regions (AgNOR) in non-small-cell cancer. We determined the area index (AI) and coefficient of variation (CV) of AgNOR. AI is associated with the key clinicomorphological parameters within the TNM system: and values, greatest tumor dimension up to 3 cm and more, disease stage, histogenesis, and tumor differentiation. CV is associated with value, greatest tumor dimension up to 3 cm and more, histogenesis, and tumor differentiation. Survival of patients is longer in low AI or CV values versus high AI or CV values, longer in low AI and CV values (−AI/−CV type), shorter in high AI and CV values (+AI/+CV type), and intermediate in opposite AI and CV values (−AI/+CV and +AI/−CV types). Independent predictors in non-small-cell lung cancer include value, greatest tumor dimension, histogenesis, and CV. Assessment of quantitative values and heterogeneity of AgNOR is important for differential diagnosis and prognosis of non-small-cell lung cancer.